BridgeBio Pharma Inc (NAS:BBIO)
$ 27.94 0.18 (0.65%) Market Cap: 5.23 Bil Enterprise Value: 6.44 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 48/100

BridgeBio Pharma Inc ATTRibute-CM Phase 3 Transcript

Aug 28, 2023 / 12:30PM GMT
Release Date Price: $28.67 (-3.40%)
Operator

Good day, and thank you for standing by. Welcome to today's discussion with BridgeBio, which will cover the company's ATTRibute-CM Phase III results as presented at ESC. Currently, all participants are in a listen-only mode. Please be advised that today's conference is being recorded.

I would now like to introduce you to the speakers for today: Julian Gillmore, MD-PhD Professor at University College London and Head of University College London Center for amyloidosis and [asomyloidosis] center research fleet; Jonathan Fox, MD-PhD Chief Medical Officer of BridgeBio Cardio Renal.

I will now hand the call over to Neil Kumar, PhD, CEO of BridgeBio. Please go ahead.

Neil Kumar
BridgeBio Pharma, Inc. - Co-Founder, President, CEO & Director

Thank you, operator, and thanks, everyone, for joining. The team has assembled here in Amsterdam, where we had the privilege of sharing further details from our ATTRibute-CM Phase III clinical trial results of acoramidis and ATTR cardiomyopathy. I used the word privilege on multiple levels. Number one, that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot